Pfizer COVID-19 vaccine safety data - Child participants Pfizer COVID-19 vaccine paediatric formulation (5-11 years) Main navigation COVID-19 vaccines Pfizer COVID-19 vaccine adult formulation Pfizer COVID-19 vaccine paediatric formulation (5-11 years) Child participants Pfizer bivalent COVID-19 vaccine Moderna COVID-19 vaccine Moderna bivalent COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines National Immunisation Program Schedule vaccines Mpox (monkeypox)vaccine Data on this page show the responses of individuals aged 5-11 years who received the paediatric 10 microgram formulation of the Pfizer COVID-19 vaccine and whose parent or carer completed an AusVaxSafety survey on their child's behalf sent on day 3 after vaccination. These data provide you with a profile of what to expect in the days following your child's Pfizer COVID-19 vaccination and can assist when planning for your child's COVID-19 vaccination. The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas. AusVaxSafety's active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website. Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here. Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021 Guidance on Myocarditis and Pericarditis after mRNA COVID-19 vaccines Comirnaty vaccine phase III trial publication AusVaxSafety will continue to closely monitor the safety data of all COVID-19 vaccines in use in Australia in conjunction with the TGA. News & events All news & events 26 February 2023 | News What is a bivalent COVID-19 vaccine and how do the short-term side effects compare to the original COVID-19 booster vaccines? 10 February 2023 | News Update to AusVaxSafety COVID-19 vaccine safety data reporting 31 January 2023 | News Short-term adverse event profile of COVID-19 mRNA vaccines in Aussie kids: reassuring data from AusVaxSafety 22 December 2022 | News How common are severe side effects from COVID vaccines? And how are they detected?